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Summary Regional chemotherapy is commonly used to treat patients with colorectal liver metastases.
However, improvement in survival has still not been demonstrated. Cytotoxic loaded albumin microspheres for
arterial administration have been described as a means of improving the therapeutic index, but their
distribution depends upon the prevailing pattern of arterial blood-flow at the time of injection. In this study,
the ability of the vasoactive drug angiotensin II to target arterially injected microspheres to colorectal liver
metastases is assessed in nine patients using scintigraphic planar and tomographic imaging.
The median tumour: normal ratio in nine patients with colorectal liver metastases was 3.4:1 before the
administration of angiotensin II. The corresponding ratio after administration of angiotensin II was 7.3:1. The
median improvement factor was 1.8 (P <0.05).
The data suggest that worthwhile tumour targeting can be achieved with angiotensin II in patients with
colorectal liver metastases.
Post-mortem studies have shown that up to 70% of patients
dying after a potentially curative resection for colorectal
cancer, die with liver metastases. The prognosis of patients
with colorectal liver metastases is generally poor, survival
being in the range of 3 to 9 months (Woods, 1984; Nielsen et
al., 1971).
Surgical resection of colorectal hepatic metastases may be
effective in patients with limited disease (Bradpiece et al.,
1987), but may not be feasible in the majority of patients
where multiple tumours are present. Although some recent
studies of combined systemic 5 fluorouracil and folinic acid
or interferon show promising results (O'Connell, 1989; Kerr,
1989; Wadler et al., 1989), conventional systemic chemo-
therapy has been associated with poor response rates. Atten-
tion has therefore turned to regional chemotherapy.
It is known that established colorectal liver metastases
receive their blood supply from the hepatic artery and the
administration of anti-cancer drugs via an indwelling hepatic
arterial catheter is now widely practised (Ridge et al., 1987).
Unfortunately, although the tumour response rates may in-
crease when chemotherapeutic agents are administered intra-
arterially rather than systemically (Berger, 1981) a significant
increase in survival among treated patients has not been
demonstrated by randomised controlled trial (Malik &
Wrigley, 1988).
Novel chemotherapeutic drug delivery systems including
cytotoxic loaded or radioactive microspheres for administra-
tion by the arterial route, have been developed. We have
previously described cytotoxic loaded albumin microspheres
(diameter 20-40IAm) which are trapped in the liver when
injected into the hepatic artery (McArdle et al., 1988; Will-
mott et al., 1985), the drug being released as the microsphere
degrades. However intra-arterial injection of such particles
results in their unselective distribution throughout the liver,
microsphere concentration within different regions of the
organ being dependent upon the prevailing distribution of
arterial blood-flow. However, if drug-loaded microspheres
could be targeted into tumours, the therapeutic advantage
might be greatly improved and systemic and hepatocellular
toxicity reduced.
Such a mechanism was described in 1985 by Sasaki and
co-workers who reported the effect of angiotensin II on
tumour blood-flow in patients with neoplastic liver disease.
Angiotensin II produces temporary vasoconstriction in nor-
mal liver arterioles. Tumour vasculature, being immature, is
unable to vasoconstrict because it lacks both an adrenergic
nerve supply and smooth muscle in the vessel wall. For a
short period during a regional angiotensin II infusion
therefore, a situation exists where particles administered by
bolus injection might be targeted effectively towards tumours.
We have previously attempted to quantitate the ability of
angiotensin II to concentrate arterially administered micro-
spheres within hepatic tumours, using a double isotope tech-
nique and biopsies obtained at laparotomy (Goldberg et al.,
1990a). Such techniques might be open to a number of
errors. In particular, sampling differences and the effects of
general anaesthesia on liver blood-flow are difficult to con-
trol. The present study was performed to gain a broader
assessment of tumour targeting within the whole liver in
conscious patients.
Method
The targeting ability of angiotensin II was estimated in 11
patients with biopsy-confirmed advanced colorectal hepatic
metastases and indwelling hepatic arterial perfusion catheters,
using standard scintographic techniques. Each patient had
three scintigraphic studies of the liver completed with single
photon emission computed tomography (SPECT):
(a) After an intravenous injection of albumin colloid.
(b) After hepatic arterial injection of radio-labelled
albumin microspheres.
(c) After hepatic arterial injection of albumin microspheres
given immediately after an arterial infusion of angio-
tensin II.
The studies were performed in random order, at least 3 days
apart and completed within a 2 week period.
The albumin colloid study was performed to localise
tumours and to assess the extent of liver involvement by
metastatic disease. Aquisition of the SPECT images was
commenced approximately 15 min after intravenous injection
of 80 MBq of 'Tc albumin colloid.
The other two studies were performed by hepatic arterial
perfusion scintigraphy (HAPS). Albumin microspheres
(2.5 mg, particle diameter 20-40 p, Sorin Biomedica) labelled
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with 80 MBq of pertechnetate (99"Tc MSA) were used.
Immediately before arterial injection, the vial ofmicrospheres
was vortexed and the dose drawn up into a glass syringe
(Goldberg et al., 1987). After particle administration, the
syringe was flushed twice with normal saline, and the catheter
heparinised to maintain patency. In one 991Tc MSA study
there was no additional patient preparation. In the other,
microsphere administration was performed immediately after
a 100 s intra-arterial infusion of angiotensin II at a rate of
0pggmin-'.
All studies were performed using an IGE 400AT tomo-
graphic gamma camera with a low energy parallel collimator,
and the images stored on a dedicated computer (MAPS 2000,
Link Analytical Ltd). Patients were positioned supine on the
tomography couch with the arms behind the head. For all
three studies, SPECT aquisition of 64 twenty-second images
at 64 pixel resolution were taken of the liver over 3600. Each
image was corrected with a uniformity flood-field of 8 x 106
counts, acquired prior to the study to accommodate for
inherent gamma camera non-uniformities. The X ADC offset
was adjusted to give a mean error of less than ± 0.16 pixels
(1 mm) for a 360° arc.
The tomographic studies were reconstructed using a Data
General Nova computer with commercial software (Link
Analytical Ltd) in which the standard ramp filter was
modified by a generalised Hamming window function with a
constant equal to 0.54. No correction was made for attenua-
tion or scatter. Since the same areas of tumour and liver were
used in the different studies on any one patient, any errors
arising from this would cancel out when enhancement ratios
were calculated.
Reconstructed transverse slices from the three scintigraphic
studies for each patient were aligned with each other as
follows. By comparing the planar anterior images from the
tomographic aquisitions, corresponding transverse slices were
identified. The slices were aligned in the remaining two
dimensions by comparing five corresponding transverse slices
from each study. Alignment was achieved for each slice by
moving the image from one study relative to a region of
interest drawn on the other, until all three studies were in
correct registration relative to one another. The average
values of the relative x and y shifts for the five sections were
then taken as the definitive amount for shifting all the slices
of a study, it being assumed that the same movement was
appropriate for each slice of a transverse set. The movement
process resulted in three sets of transverse slices per patient
which could be superimposed to within a single pixel mis-
match in any dimension. Relative rotation of iiages was not
necessary.
To check the alignment and also to assess the localisation
of microspheres in tumour, images from the colloid study
and from each of the microsphere studies were combined on
the computer and displayed in different colours using the
commercial software (Figures 1-4).
Since albumin colloid is taken up by normal liver tissue
while miscrospheres administered via the hepatic artery often
concentrate in tumour regions, a true whole liver outline was
obtained by superimposing colloid and microsphere images.
The intensities of the three studies were adjusted before
creating a composite image in order to visualise all of the
components. The whole liver outline was defined on the
composite image for each slice.
Because albumin colloid is taken up by functioning
hepatocytes, tumour regions are seen as cavitations within
the liver image (Figures 1 and 2). On each slice of the
albumin colloid study regions of interest were drawn to
define normal liver and tumour areas. Tumour regions were
defined as being regions of low uptake on the albumin col-
Figure 1 Anterior planer views of three studies in one patient: (i) Albumin colloid. (Top left). (ii) Hepatic arterial perfusion
scintigraphy. (Top right). (iii) Angiotensin II enhanced hepatic arterial perfusion scintigraphy. (Bottom).116 J.A. GOLDBERG et al.
Figure 2 Comparative transaxial slices (same studies as Figure 1): (i) Albumin colloid. (Top left). (ii) Hepatic arterial perfusion
scintigraphy. (Top right). (iii) Angiotensin II enhanced hepatic arterial perfusion scintigraphy. (Bottom).
loid slice. The remainder of the organ was taken to be
normal liver parenchyma. A region of interest of approxi-
mately five pixels diameter was defined over an area of
uniformly high uptake on each colloid slice and used as a
sample of normal liver to quantitate the activity ratios of
tumour and normal liver.
The regions as defined above on a slice of the albumin
colloid scan (whole- liver, normal liver, tumours) were
superimposed on the corresponding slices of both micro-
sphere studies (Figure 3). The activity within these regions
was used to estimate the ratio of activity in normal and
tumour regions of both the simple and the angiotensin II
enhanced microsphere studies. The improvement with
angiotensin II was estimated as the ratio of these two
tumour:normal count density ratios. Every tumour was
assessed within the liver at its largest diameter on transverse
reconstruction. The tumour diameter was defined as the
diameter of a circle with the same area as the actual region of
interest drawn around the tumour.
Results
Two patients had markedly hypervascular tumours and the
counts in their normal liver regions on one or both micro-
sphere studies were exceedingly low or at background level,
irrespective of whether angiotenin II had been used. The
tumour:normal ratio before angiotensin II in these two
patients was 30:1 and infinity respectively. Sufficient normal
liver counts could not be obtained in either patient even
when the 'normal' liver sample was taken to be the whole
slice less the tumour regions, after angiotensin II had been
given.
In the remaining nine patients, 48 tumours were indivi-
dually assessed, ranging in diameter from approximately
4.5-10 cm, as measured from the colloid images, thereby
avoiding the problems of quantitating deposits at the limits
of resolution of the system.
In Figure 5, the ratio of activity between tumour and
normal liver can be seen for each tumour, before and after
angiotensin II. Figure 6 demonstrates the targeting power of
angiotensin II in all 48 tumours.
Table I shows the median value of tumour:normal ratio
for each patient before and after angiotensin II and also the
median improvement in tumour:normal ratio for each patient.
The median tumour:normal ratio before angiotensin II
was 3.4:1 (range 1.3-6.0) among the nine patients, whereas
the median ratio after angiotensin II was 7.3:1 (range
1.5-8.8). This difference was significant by the Wilcoxon test
for paired samples (P<0.05). The median improvement in
tumour:normal ratio of microsphere bound activity after
angiotensin II was by a factor of 1.8 (range 0.9-3.4). No
relationship was found between the success in targeting with
angiotensin II and tumour diameter.
In addition to the 48 tumours described above, there were
three with hypervascular shells and relatively hypovascular
cores, all ofwhich were more than 5 cm in diameter (Figure 4).
Although the cores were hypovascular relative to the rim,
they were always hypervascular relative to the normal liver.
These were difficult to quantitate with any degree ofcertainty
because the resolution of the image acquisition system was
not sufficient to clearly define the boundary between the core
and shell regions within the tumour. However, within these
three tumours, the count density when angiotensin II was
used appeared to increase to a greater extent within the
central hypovascular core than within the shell regionANGIOTENSIN II IN TUMOUR TARGETING 117
Figure 3 Computer aligned composite of the albumin colloid slice (green) and the angiotensin II enhanced microsphere study (red)
(from Figure 2), illustrating the reciprocity of the two scans and accurate tumour targeting.
(median core:rim ratio ofenhancement ratios was 1.26, range
0.93-1.49; six readings).
Discussion
The technique for defining the regions of interest for tumour
and normal liver tissue was crucial to this analysis of
targeting. The definition of the whole liver outline was
straightforward. There are, however, potential pitfalls in the
definition of tumour and normal liver regions which merit
further discussion.
During image reconstruction, no correction was made for
attenuation or scatter but both of these will have some effect
on the measured count densities of the tumour and normal
regions which we defined. In particular, quantitation of the
'hypovascular' core of a tumour with a markedly hypervas-
cular rim may overestimate the activity within the core. The
proximity of the selected region of normal tissue to tumours,
and the positions of both normal and tumour regions within
the liver must also be considered. In patients with a large
volume of liver affected by metastatic disease, or with diffuse
tumour, an area of apparently normal liver which was not
close to tumour was sometimes difficult to select.
The proximity of normal liver tissue to tumour is also
worthy of consideration on physical and physiological
grounds. If the selected normal region is very close to a
tumour, it may contain counts due to gamma rays scattered
from the tumour area or due to artifacts from the back
projection process. This may result in the generation of a
significant background level. This would have the effect of
increasing the counts in the normal region close to a tumour,
thereby reducing the ratio of activity in tumour to that in
normal liver.
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Figure 5 Tumour: normal liver ratio (T:N ratio) of activity
before and after the administration of angiotensin II in 48 colo-
rectal hepatic metastases (nine patients).
These considerations would suggest that a normal region
should not be selected immediately adjacent to tumour
regions when possible. However, if the normal region were at
the surface of the liver and the tumour regions deeper within
the organ, the effect of attenuation by the surrounding tissue
would result in a reduced count density for the deeper
tumour regions and the tumour:normal ratio would be
decreased.
We defined our normal regions close enough to tumour
regions so that differences in attenuation did not significantly
effect count densities, but where possible, not so close that118 J.A. GOLDBERG et al.
Figure 4 Computer aligned composite of an albumin colloid slice (green) and corresponding angiotensin II enhanced microsphere
slice (red), illustrating a tumour with a hypervascular shell and hypovascular core and accurate tumour therapy.
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Table I Improvement in tumour uptake of microspheres in nine
patients after angiotensin II
T:N ratio T:N Ratio Improvement in ratio
Before AII After All After AII
Patient (Median) (Median) (Median)
1 1.60 3.36 2.98
2 3.96 7.62 1.92
3 6.04 8.10 1.11
4 3.73 1.54 0.52
5 3.40 8.82 3.41
6 2.57 7.61 3.03
7 1.33 2.64 1.77
8 4.65 7.32 1.74
9 2.44 2.61 0.86
7 8 9
Figure 6 The 'improvement' in tumour targeting in 48 colorectal
hepatic metastases (nine patients).
Improvement =Activity in tumour: Activity in liver after angiotensin II
Activity in tumour: Activity in liver before angiotensin II
our results were likely to be affected by physiological changes
occurring in the normal liver tissue immediately surrounding
tumours, or by scatter.
During processing, the images from tumour and normal
regions were examined in detail and the effects of the
angiotensin II infusion noted. The angiotensin II infusion
often appeared to sharpen the tumour outline, thereby slight-
ly reducing the area of the tumour image (compare Figures
2ii and 2iii). One effect of this was to reduce the number of
pixels with increased uptake in the angiotensin II study. The
corresponding count density (which is calculated using the
original number ofpixels) was therefore diluted by the empty
pixels surrounding the smaller area of increased uptake. This
in turn may have led to underestimation of the degree of
enhancement produced by angiotensin II.
It is wothy of note that the two patients where angiotensin
II enhancement could not be evaluated had exceptionally
hypervascular tumours. Whether angiotensin II augmented
microsphere concentration within tumours in these patients is
largely academic, in view of the efficient delivery of particles
to tumour regions under physiological conditions of arterial
perfusion.
Any manoeuvre which improves the relative exposure of
tumour regions to arterially administered therapeutic agents
and reduces hepatotoxicity is likely to improve the regional
advantage if the thresholds for drug extraction or metabolism
are not exceeded. The temporary nature of the angiotensin II
targeting mechanism is ideally suited to bolus injection of
microspheres. Targeting would be particularly valuable in a
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system where a 'sustained release' mechanism of drug
administration is in operation, since toxicity in normal tissues
may become problematical with continuing and extended
drug exposure.
Potential limitations of the use of cytotoxic loaded micro-
spheres in regional hepatic therapy include an increase in
arterio-venous shunting within the organ, causing relative
loss of regional advantage as the particles enter the systemic-
venous circulation and embolise in the pulmonary tissues.
However, we have recently shown that base-line shunting in
patients with colorectal liver metastases is low and not
significantly increased following the regional administration
of a 'therapeutic' dose of microspheres (Goldberg et al.,
1990b). In clinical practice therefore, we have not found
arteriovenous shunting to be a problem.
Clearly, this technique will not offer a solution to all
patients, since many patients with liver metastases have
occult disease elsewhere. However, data from natural history
studies suggest that between 20 and 30% of patients with
colorectal liver metastases might benefit from hepatic arterial
therapy, since this is the proportion of patients in whom
disease is thought to be confined to the liver (Welch &
Donaldson, 1979; Daly et al., 1985).
In conclusion, we have demonstrated that angiotensin II
significantly increases the uptake of microspheres by tumour
in patients with colorectal liver metastases. This is likely to
enhance the tumour response to cytotoxic loaded micros-
pheres, and reduce hepatotoxicity. We are currently exploring
the use of angiotensin II in association with cytotoxic-loaded
microspheres in patients with colorectal liver metastases.
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